BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

724 related articles for article (PubMed ID: 23150224)

  • 1. Chimeric hepatitis B virus/hepatitis C virus envelope proteins elicit broadly neutralizing antibodies and constitute a potential bivalent prophylactic vaccine.
    Beaumont E; Patient R; Hourioux C; Dimier-Poisson I; Roingeard P
    Hepatology; 2013 Apr; 57(4):1303-13. PubMed ID: 23150224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunizations with chimeric hepatitis B virus-like particles to induce potential anti-hepatitis C virus neutralizing antibodies.
    Vietheer PT; Boo I; Drummer HE; Netter HJ
    Antivir Ther; 2007; 12(4):477-87. PubMed ID: 17668556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric hepatitis B and C viruses envelope proteins can form subviral particles: implications for the design of new vaccine strategies.
    Patient R; Hourioux C; Vaudin P; Pagès JC; Roingeard P
    N Biotechnol; 2009 Apr; 25(4):226-34. PubMed ID: 19356608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutralization effects of antibody elicited by chimeric HBV S antigen viral-like particles presenting HCV neutralization epitopes.
    Wei S; Lei Y; Yang J; Wang X; Shu F; Wei X; Lin F; Li B; Cui Y; Zhang H; Wei S
    Vaccine; 2018 Apr; 36(17):2273-2281. PubMed ID: 29576303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutralizing antibodies induced by cell culture-derived hepatitis C virus protect against infection in mice.
    Akazawa D; Moriyama M; Yokokawa H; Omi N; Watanabe N; Date T; Morikawa K; Aizaki H; Ishii K; Kato T; Mochizuki H; Nakamura N; Wakita T
    Gastroenterology; 2013 Aug; 145(2):447-55.e1-4. PubMed ID: 23673355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Recombinant Hepatitis C Virus Genotype 1a E1/E2 Envelope Glycoprotein Vaccine Elicits Antibodies That Differentially Neutralize Closely Related 2a Strains through Interactions of the N-Terminal Hypervariable Region 1 of E2 with Scavenger Receptor B1.
    Johnson J; Freedman H; Logan M; Wong JAJ; Hockman D; Chen C; He J; Beard MR; Eyre NS; Baumert TF; Tyrrell DL; Law JLM; Houghton M
    J Virol; 2019 Nov; 93(22):. PubMed ID: 31462563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric hepatitis B virus (HBV)/hepatitis C virus (HCV) subviral envelope particles induce efficient anti-HCV antibody production in animals pre-immunized with HBV vaccine.
    Beaumont E; Roingeard P
    Vaccine; 2015 Feb; 33(8):973-6. PubMed ID: 25596457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incorporation of apolipoprotein E into HBV-HCV subviral envelope particles to improve the hepatitis vaccine strategy.
    Gomez-Escobar E; Burlaud-Gaillard J; Visdeloup C; Ribeiro E Silva A; Coutant P; Roingeard P; Beaumont E
    Sci Rep; 2021 Nov; 11(1):21856. PubMed ID: 34750487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity of Leishmania-derived hepatitis B small surface antigen particles exposing highly conserved E2 epitope of hepatitis C virus.
    Czarnota A; Tyborowska J; Peszyńska-Sularz G; Gromadzka B; Bieńkowska-Szewczyk K; Grzyb K
    Microb Cell Fact; 2016 Apr; 15():62. PubMed ID: 27075377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression, purification and immunogenic characterization of hepatitis C virus recombinant E1E2 protein expressed by Pichia pastoris yeast.
    Cai W; Su L; Liao Q; Ye L; Wu Y; Wu Z; She Y
    Antiviral Res; 2010 Oct; 88(1):80-5. PubMed ID: 20691736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of the E2 Hypervariable Region (HVR1) in the Immunogenicity of a Recombinant Hepatitis C Virus Vaccine.
    Law JLM; Logan M; Wong J; Kundu J; Hockman D; Landi A; Chen C; Crawford K; Wininger M; Johnson J; Mesa Prince C; Dudek E; Mehta N; Tyrrell DL; Houghton M
    J Virol; 2018 Jun; 92(11):. PubMed ID: 29540595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Hepatitis C Virus DNA Vaccine Encoding a Secreted, Oligomerized Form of Envelope Proteins Is Highly Immunogenic and Elicits Neutralizing Antibodies in Vaccinated Mice.
    Masavuli MG; Wijesundara DK; Underwood A; Christiansen D; Earnest-Silveira L; Bull R; Torresi J; Gowans EJ; Grubor-Bauk B
    Front Immunol; 2019; 10():1145. PubMed ID: 31178869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral immunization with attenuated Salmonella carrying a co-expression plasmid encoding the core and E2 proteins of hepatitis C virus capable of inducing cellular immune responses and neutralizing antibodies in mice.
    Cao J; Chen Z; Ren Y; Luo Y; Cao M; Lu W; Zhao P; Qi Z
    Vaccine; 2011 May; 29(20):3714-23. PubMed ID: 21396407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Live and killed rhabdovirus-based vectors as potential hepatitis C vaccines.
    Siler CA; McGettigan JP; Dietzschold B; Herrine SK; Dubuisson J; Pomerantz RJ; Schnell MJ
    Virology; 2002 Jan; 292(1):24-34. PubMed ID: 11878905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mixing particles from various HCV genotypes increases the HBV-HCV vaccine ability to elicit broadly cross-neutralizing antibodies.
    Beaumont E; Joël Clément B; Guérin V; Chopin L; Roch E; Gomez-Escobar E; Roingeard P
    Liver Int; 2020 Aug; 40(8):1865-1871. PubMed ID: 32458507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunoreactivity of HCV/HBV epitopes displayed in an epitope-presenting system.
    Chen Y; Xiong X; Liu X; Li J; Wen Y; Chen Y; Dai Q; Cao Z; Yu W
    Mol Immunol; 2006 Feb; 43(5):436-42. PubMed ID: 16337486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incorporation of primary patient-derived glycoproteins into authentic infectious hepatitis C virus particles.
    Doerrbecker J; Friesland M; Riebesehl N; Ginkel C; Behrendt P; Brown RJ; Ciesek S; Wedemeyer H; Sarrazin C; Kaderali L; Pietschmann T; Steinmann E
    Hepatology; 2014 Aug; 60(2):508-20. PubMed ID: 24771613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-glycosylation-mutated HCV envelope glycoprotein complex enhances antigen-presenting activity and cellular and neutralizing antibody responses.
    Ren Y; Min YQ; Liu M; Chi L; Zhao P; Zhang XL
    Biochim Biophys Acta; 2016 Aug; 1860(8):1764-75. PubMed ID: 26278021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New neutralizing antibody epitopes in hepatitis C virus envelope glycoproteins are revealed by dissecting peptide recognition profiles.
    Kachko A; Kochneva G; Sivolobova G; Grazhdantseva A; Lupan T; Zubkova I; Wells F; Merchlinsky M; Williams O; Watanabe H; Ivanova A; Shvalov A; Loktev V; Netesov S; Major ME
    Vaccine; 2011 Dec; 30(1):69-77. PubMed ID: 22041300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Study of neutralization antibodie induced by DNA vaccine of HCV envelope protein 2 in mice].
    Shao S; Zhou H; Tong Y; Ren Y; Chen Z
    Wei Sheng Yan Jiu; 2011 May; 40(3):295-8. PubMed ID: 21695897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.